Revolution Medicines' Earnings Call: Competitive Profile, Head-to-Head Trial Necessity Signals Don't Match

Date of Call: Aug 5, 2026

Guidance:

• Full-year 2026 GAAP operating expenses expected to be between $2.1B and $2.2B, including non-cash stock-based compensation of $270-$290M.
• Accelerating manufacturing for clinical and commercial supply of deraxon RASIB and zoldon RASIB.
• Increasing investment in commercial readiness and international infrastructure.

Business Commentary:

Pancreatic Cancer Progress:

• Revolution Medicines reported compelling results from the Resolute 302 trial, demonstrating statistically significant and clinically meaningful improvements in overall survival, progression-free survival, and quality-of-life indicators for patients with previously treated metastatic pancreatic cancer.
• The results led to the FDA accepting the new drug application for Deraxon RASIB and the activation of an expanded access program across nearly all 50 US states and Puerto Rico, with over 2,000 patients approved.
• The progress is attributed to the strong clinical data and the company's urgent efforts to expand treatment availability.

Non-Small Cell Lung Cancer Development:

• The company's Duraxanracid monotherapy received a Breakthrough Therapy Designation from the FDA for treated metastatic non-small cell lung cancer with KRAS mutations other than G12C.
• Encouraging phase 1-2 results led to the initiation of the RESOLVE-301 global phase 3 study, with plans to advance mutant-selective inhibitors into registrational development.
• The development strategy is driven by the recognition of significant unmet needs in RAS-driven non-small cell lung cancer and the potential of RAS on mutant-selective inhibitors.

Financial Position and Investment:

• Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments, including proceeds from public offerings and a royalty tranche from Royalty Pharma.
• The company reported a net loss of $644 million for Q2 2026, primarily due to increased R&D and G&A expenses related to clinical trials and commercial preparations.
• The strong financial position allows for increased investment in manufacturing, clinical development, and commercial readiness to support potential U.S. and international launches.

Regulatory and Commercial Readiness:

• The U.S. FDA accepted the full NDA submission for Deraxon RASIB, and the European Medicines Agency initiated a phased review, designating it a high priority under the Cancer Medicines Pathfinder project.
• The company is well-prepared for a potential launch with a fully operational sales organization, field access team, and patient services program.
• Regulatory progress and commercial readiness are critical to executing a successful launch and delivering treatment to patients quickly.

Sentiment Analysis:

Overall Tone: Positive

• Management described 2026 as a transformational year with 'substantial progress' and 'unprecedented clinical results' in pancreatic cancer. They noted the FDA accepted the NDA, the EMA initiated a phased review, and the company is 'well-positioned to execute a successful launch' and 'redefine what is possible for patients with RAS-driven cancers.'

Q&A:

• Question from Mark Fromm (TD Cowen): Regarding colorectal cancer (CRC), what's the latest thought on proof of concept, especially after Adagrasib's confirmatory trial failure? Also, in lung cancer, how do you plan to position your G12C inhibitor against existing first-line trials?
  Response: Deferred CRC question for later. For lung cancer, deraxon RASIB has a highly competitive profile in monotherapy and combination, with the mutant-selective portfolio targeting over 70% of RAS mutant patients.

• Question from Charles Zhu (LifeSci Capital): How will you position multi-selective RAS inhibitors in frontline non-small cell lung cancer (NSCLC) given the focus on mutant-selective agents?
  Response: All possibilities are still on the table; the company is pursuing both multi- and mutant-selective inhibitors to create optionality and will not make premature decisions on exclusive commitments.

• Question from Michael Schmidt (Guggenheim): Any early feedback from the expanded access program (EAP) on deraxon RASIB, and what are the regulatory timelines in Europe?
  Response: No quantitative feedback; anecdotal evidence is positive. The EMA's phased review is intended to be expedited, but the timeline is not specified.

• Question from Faisal Khurshid (Jefferies): What are your latest thoughts on the PRMT5 combination data and whether you need a PRMT5 inhibitor in your own portfolio?
  Response: The PRMT5 combination is biologically intriguing, supported by preclinical and initial clinical data; the company does not need a PRMT5 inhibitor as there are many options externally and deraxon RASIB should be the backbone of therapy.

• Question from Alex Stranahan (Bank of America): Which data was shared with the FDA for the breakthrough therapy designation in NSCLC, and any thoughts on pricing for combinations with lower deraxon RASIB doses?
  Response: Cannot specify the exact data shared with the FDA. Pricing discussions are too early as no combination is approaching commercialization.

• Question from Laura Prendergast (Stifel): What does 'visibility into CRC development strategy' in Q4 entail, and are there plans for tumor-agnostic approaches beyond the big three indications?
  Response: The Q4 update will include data and plans for CRC. The company is interested in tumors outside the big three, but strategy will vary by indication, with focus currently on pancreatic cancer, lung cancer, and colorectal cancer.

• Question from Leonid Timishev (RBC): How is the commercial sales force sized for pancreatic cancer, and what is the cadence of EAP patient enrollment?
  Response: The sales force is around 60 for PDAC launch, with broad infrastructure applicable to future indications. The EAP grew from a trickle to over 2,000 patients, with high site and patient interest.

Contradiction Point 1

Characterization of Eluron RASIB's Competitive Profile

Contradiction on whether the profile is "highly competitive" or "very good," impacting perceptions of the drug's differentiation and potential in lung cancer.

Mark Fromm (TD Cowen) - Mark Fromm (TD Cowen)

2026Q2: For lung cancer, Eluron RASIB shows a highly competitive profile in combination with pembrolizumab and chemotherapy... - Alan Sandler(CDO)

What are your latest thoughts on the proof of concept in colorectal and lung cancers, and how does your approach with Eluron RASIB offer differentiation and advantages? - Marc Frahm (TD Cowen)

2026Q2: Elironrasib shows a very good safety and efficacy profile. The decision to advance is data-driven, based on highly competitive monotherapy and combination data... - Alan Sandler(CDO)

Contradiction Point 2

Necessity of a PRMT5 Inhibitor in the Company's Portfolio

Contradiction on whether a PRMT5 inhibitor is needed, with a shift from "not needed" to "not needed," indicating no change but potential investor confusion.

Faisal Khurshid (Jefferies) - Faisal Khurshid (Jefferies)

2026Q2: They do not believe they need a PRMT5 inhibitor in their own portfolio at this time... - Alan Sandler(CDO)

What are your latest thoughts on the PRMT5 combination data with Tango Therapeutics and whether a PRMT5 inhibitor is needed in your portfolio? - Faisal Khurshid (Jefferies)

2026Q2: A PRMT5 inhibitor is not considered necessary in RevMed's portfolio... - Alan Sandler(CDO)

Contradiction Point 3

Commitment to Specific Treatment Regimens

Contradiction on premature commitment to treatment regimens for RAS inhibitors, affecting strategic clarity and trial design.

Charles Zhu (LifeSci Capital) - Charles Zhu (LifeSci Capital)

2026Q2: All treatment options are still on the table... It is premature to make commitments to specific regimens. - Alan Sandler(CDO)

How do you plan to position RAS multi-selective inhibitors alongside mutant-selective inhibitors for frontline NSCLC, and is it premature to commit to specific regimens? - Marc Frahm (TD Cowen)

2026Q1: Chemotherapy remains the standard of care until regulatory approval shifts the bar... The combination trial (309) is for the 40% of pancreatic cancers with RAS G12D mutations. The company is also running a 1L monotherapy trial (303) with daraxonrasib. Offering multiple options allows doctors to choose based on individual patient needs, even if outcomes appear similar in broad populations. - Mark Goldsmith(CEO) and Alan Sandler(CDO)

Contradiction Point 4

Necessity of a Head-to-Head Trial with a Competitor G12C Inhibitor

Contradiction on the need to conduct a trial directly comparing to a competitor's drug, impacting trial design and competitive positioning.

Kalpit (Guggenheim) - Kalpit (Guggenheim)

2026Q2: Given Roche’s head-to-head win against Sotiracib and Adagrasib in the CRESCENDO-1 trial, do you think you’d need to run a trial against Diveracib (a G12C inhibitor)?... The control arm in a study is dictated by the current standard of care at the time of initiation, which requires a full approval. Since that is not the case currently, they do not feel it is necessary to run such a trial. - Alan Sandler(CDO)

"Following Roche's head-to-head success in the CRESCENDO-1 trial against Sotiracib and Adagrasib, is a trial against Diveracib (a G12C inhibitor) necessary?" - Marc Frahm (TD Cowen)

2026Q1: Chemotherapy remains the standard of care until regulatory approval shifts the bar... The combination trial (309) is for the 40% of pancreatic cancers with RAS G12D mutations. The company is also running a 1L monotherapy trial (303) with daraxonrasib. Offering multiple options allows doctors to choose based on individual patient needs, even if outcomes appear similar in broad populations. - Mark Goldsmith(CEO) and Alan Sandler(CDO)

Contradiction Point 5

Colorectal Cancer (CRC) Development Strategy Clarity

Contradiction on providing a clear, specific development path for CRC, affecting investor confidence and strategic direction.

Laura Prendergast (Stifel) - Laura Prendergast (Stifel)

2026Q2: In Q4, they will share data and outline their development plans... Investors will form their own impressions. - Alan Sandler(CDO)

Can you clarify the expected visibility into the CRC development strategy in Q4 and whether there's conviction in the registrational path? - Jay Olson (Oppenheimer)

20260226-2025 Q4: Colorectal cancer (CRC) has not been deprioritized... The preferred approach is to develop combinations... to registration independently. - Stephen Kelsey(President of R&D), Mark Goldsmith(CEO)